全文获取类型
收费全文 | 1188篇 |
免费 | 104篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 42篇 |
妇产科学 | 24篇 |
基础医学 | 192篇 |
口腔科学 | 72篇 |
临床医学 | 150篇 |
内科学 | 192篇 |
皮肤病学 | 10篇 |
神经病学 | 64篇 |
特种医学 | 73篇 |
外科学 | 185篇 |
综合类 | 35篇 |
预防医学 | 88篇 |
眼科学 | 4篇 |
药学 | 89篇 |
中国医学 | 1篇 |
肿瘤学 | 72篇 |
出版年
2022年 | 7篇 |
2021年 | 17篇 |
2020年 | 21篇 |
2019年 | 25篇 |
2018年 | 24篇 |
2017年 | 19篇 |
2016年 | 21篇 |
2015年 | 31篇 |
2014年 | 32篇 |
2013年 | 40篇 |
2012年 | 52篇 |
2011年 | 65篇 |
2010年 | 40篇 |
2009年 | 39篇 |
2008年 | 54篇 |
2007年 | 55篇 |
2006年 | 37篇 |
2005年 | 44篇 |
2004年 | 46篇 |
2003年 | 42篇 |
2002年 | 30篇 |
2001年 | 48篇 |
2000年 | 29篇 |
1999年 | 33篇 |
1998年 | 19篇 |
1997年 | 17篇 |
1996年 | 22篇 |
1995年 | 17篇 |
1994年 | 16篇 |
1993年 | 11篇 |
1992年 | 26篇 |
1991年 | 28篇 |
1990年 | 15篇 |
1989年 | 15篇 |
1988年 | 12篇 |
1987年 | 23篇 |
1986年 | 27篇 |
1985年 | 17篇 |
1984年 | 16篇 |
1983年 | 12篇 |
1982年 | 13篇 |
1981年 | 9篇 |
1980年 | 8篇 |
1979年 | 10篇 |
1978年 | 10篇 |
1976年 | 8篇 |
1973年 | 12篇 |
1972年 | 13篇 |
1970年 | 8篇 |
1966年 | 8篇 |
排序方式: 共有1301条查询结果,搜索用时 15 毫秒
1.
A W Biglan R Gonnering L B Lockhart B Rabin F H Fuerste 《American journal of ophthalmology》1986,101(2):232-235
To test the possibility of the formation of an antibody to botulinum A toxin after multiple injections of this potent neurotoxin, we collected serum samples from 28 patients who received 57 doses. These injections over a nine-month period with as much as 50 units per injection formed no detectable antibody. 相似文献
2.
3.
Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand
PA Crock JD McKenzie AM Nicoll NJ Howard W Cutfield LK Shield G Byrne 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(4):381-386
Benign intracranial hypertension (BIH) is reported in three children from Australia and one from New Zealand, who were being treated with recombinant human growth hormone (rhGH). Three males and one female, aged between 10.5 and 14.2 y, developed intracranial hypertension within 2 weeks to 3 months of starting treatment. A national database, OZGROW, has been prospectively collecting data on all 3332 children treated with rhGH in Australia and New Zealand from January 1986 to 1996. The incidence of BIH in children treated with growth hormone (GH) is small, 1.2 per 1000 cases overall, but appears to be greater with biochemical GHD (<10IUml -1 ), i.e. 6.5/1000 (3 in 465 cases), relative risk 18.4, 95% confidence interval 1.9-176.1, than in all other children on the database. The incidence in patients with Turner's syndrome was 2.3/1000 (1 in 428 cases). No cases in patients with partial GHD (10–20 IUml -1 ) or chronic renal failure were identified. Possible causative mechanisms are discussed. The authors'practice is now to start GH replacement at less than the usual recommended dose of 14IUm-2 week-1 in those children considered to be at high risk of developing BIH. Ophthalmological evaluation is recommended for children before and during the first few months following commencement of rhGH therapy and is mandatory in the event of peripheral or facial oedema, persistent headaches, vomiting or visual symptoms. The absence of papilledema does not exclude the diagnosis. 相似文献
4.
5.
Chemotherapeutics have been shown to have detrimental effects on immune response, hence, pretreatment or concurrent use of an immune augmentation substance could lead to reconstitution of an immune response such as cytolytic activity after administration of chemotherapeutic agent. Previously, in an in vitro system, we have demonstrated IL-2 pretreatment reconstituted drug induced immunosuppression as well as altered differential sensitivities to chemotherapeutic agents. This study presents evidence that in vivo functional cytolytic potential can be retained by IL-2 pretreatment on chemotherapeutically-induced natural cytolytic hyporesponsiveness. 相似文献
6.
7.
8.
9.
10.